The World Health Organization has approved clinical trials for two Ebola vaccine candidates developed by the University of Oxford with the Serum Institute of India and Moderna. The trials will be conducted in the Democratic Republic of the Congo, led by its National Institute for Biomedical Research and supported by international partners. The outbreak, caused by the Bundibugyo virus, has infected over 10,000 people since May and killed 5,103, a fatality rate above 50%. Several countries, including Ghana and the United States, have imposed travel bans on arrivals from the DRC, a step the WHO has criticized.
Uganda
3 stories since 28 October 2026, newest first
4 November 2026
2 November 2026
The outbreak has killed 5,376 people, most of them in the Democratic Republic of Congo, while Kenya reported nine infections in October, its first Ebola cases, and Nigeria confirmed a case in a 42‑year‑old Swiss woman. Since May, more than 10,000 individuals have been infected across the region, and the fatality rate exceeds 50%. Clinical trials of the Ervebo vaccine have started targeting the Bundibugyo strain.
28 October 2026
Health authorities in the Democratic Republic of Congo report 10,060 Ebola infections and 4,887 deaths since the outbreak was declared in mid-May. Cases have also been confirmed in Kenya, Nigeria and Uganda, with Kenya reporting nine cases and two deaths. At least 2,600 patients have recovered. The outbreak is caused by the Bundibugyo strain, for which no approved vaccine or specific treatment exists. Ituri and North Kivu provinces account for most reported cases, and Africa CDC calls it the fastest-growing Ebola outbreak in history.